Cargando…
Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)—intervention study protocol
Targeting molecular processes of aging will enable people to live healthier and longer lives by preventing age-related diseases. Geroprotectors are compounds with the potential to increase healthspan and lifespan. Even though many of them have been tested in animal models, the translation to humans...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643463/ https://www.ncbi.nlm.nih.gov/pubmed/37217632 http://dx.doi.org/10.1007/s11357-023-00813-6 |
_version_ | 1785147120371630080 |
---|---|
author | Sandalova, Elena Goh, Jorming Lim, Zi Xiang Lim, Zhi Meng Barardo, Diogo Dorajoo, Rajkumar Kennedy, Brian K. Maier, Andrea B. |
author_facet | Sandalova, Elena Goh, Jorming Lim, Zi Xiang Lim, Zhi Meng Barardo, Diogo Dorajoo, Rajkumar Kennedy, Brian K. Maier, Andrea B. |
author_sort | Sandalova, Elena |
collection | PubMed |
description | Targeting molecular processes of aging will enable people to live healthier and longer lives by preventing age-related diseases. Geroprotectors are compounds with the potential to increase healthspan and lifespan. Even though many of them have been tested in animal models, the translation to humans is limited. Alpha-Ketoglutarate (AKG) has been studied widely in model animals, but there are few studies testing its geroprotective properties in humans. ABLE is a double blinded placebo-controlled randomized trial (RCT) of 1 g sustained release Ca-AKG versus placebo for 6 months of intervention and 3 months follow up including 120 40–60-year-old healthy individuals with a higher DNA methylation age compared to their chronological age. The primary outcome is the decrease in DNA methylation age from baseline to the end of the intervention. A total of 120 participants will be randomized to receive either sustained release Ca-AKG or placebo. Secondary outcomes include changes in the inflammatory and metabolic parameters in blood, handgrip strength and leg extension strength, arterial stiffness, skin autofluorescence, and aerobic capacity from baseline to 3 months, 6 months, and 9 months. This study will recruit middle-aged participants with an older DNA methylation age compared to their chronological age, and test whether supplementation with Ca-AKG can reduce DNA methylation age. This study is unique in its inclusion of biologically older participants. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11357-023-00813-6. |
format | Online Article Text |
id | pubmed-10643463 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-106434632023-11-15 Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)—intervention study protocol Sandalova, Elena Goh, Jorming Lim, Zi Xiang Lim, Zhi Meng Barardo, Diogo Dorajoo, Rajkumar Kennedy, Brian K. Maier, Andrea B. GeroScience Original Article Targeting molecular processes of aging will enable people to live healthier and longer lives by preventing age-related diseases. Geroprotectors are compounds with the potential to increase healthspan and lifespan. Even though many of them have been tested in animal models, the translation to humans is limited. Alpha-Ketoglutarate (AKG) has been studied widely in model animals, but there are few studies testing its geroprotective properties in humans. ABLE is a double blinded placebo-controlled randomized trial (RCT) of 1 g sustained release Ca-AKG versus placebo for 6 months of intervention and 3 months follow up including 120 40–60-year-old healthy individuals with a higher DNA methylation age compared to their chronological age. The primary outcome is the decrease in DNA methylation age from baseline to the end of the intervention. A total of 120 participants will be randomized to receive either sustained release Ca-AKG or placebo. Secondary outcomes include changes in the inflammatory and metabolic parameters in blood, handgrip strength and leg extension strength, arterial stiffness, skin autofluorescence, and aerobic capacity from baseline to 3 months, 6 months, and 9 months. This study will recruit middle-aged participants with an older DNA methylation age compared to their chronological age, and test whether supplementation with Ca-AKG can reduce DNA methylation age. This study is unique in its inclusion of biologically older participants. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11357-023-00813-6. Springer International Publishing 2023-05-23 /pmc/articles/PMC10643463/ /pubmed/37217632 http://dx.doi.org/10.1007/s11357-023-00813-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Sandalova, Elena Goh, Jorming Lim, Zi Xiang Lim, Zhi Meng Barardo, Diogo Dorajoo, Rajkumar Kennedy, Brian K. Maier, Andrea B. Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)—intervention study protocol |
title | Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)—intervention study protocol |
title_full | Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)—intervention study protocol |
title_fullStr | Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)—intervention study protocol |
title_full_unstemmed | Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)—intervention study protocol |
title_short | Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)—intervention study protocol |
title_sort | alpha-ketoglutarate supplementation and biological age in middle-aged adults (able)—intervention study protocol |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643463/ https://www.ncbi.nlm.nih.gov/pubmed/37217632 http://dx.doi.org/10.1007/s11357-023-00813-6 |
work_keys_str_mv | AT sandalovaelena alphaketoglutaratesupplementationandbiologicalageinmiddleagedadultsableinterventionstudyprotocol AT gohjorming alphaketoglutaratesupplementationandbiologicalageinmiddleagedadultsableinterventionstudyprotocol AT limzixiang alphaketoglutaratesupplementationandbiologicalageinmiddleagedadultsableinterventionstudyprotocol AT limzhimeng alphaketoglutaratesupplementationandbiologicalageinmiddleagedadultsableinterventionstudyprotocol AT barardodiogo alphaketoglutaratesupplementationandbiologicalageinmiddleagedadultsableinterventionstudyprotocol AT dorajoorajkumar alphaketoglutaratesupplementationandbiologicalageinmiddleagedadultsableinterventionstudyprotocol AT kennedybriank alphaketoglutaratesupplementationandbiologicalageinmiddleagedadultsableinterventionstudyprotocol AT maierandreab alphaketoglutaratesupplementationandbiologicalageinmiddleagedadultsableinterventionstudyprotocol |